A side-by-side reading of BPC-157 and TB-500 from our profiles: origin, mechanism, studied uses and evidence status. No recommendations — only what the sources say.
Key parameters side by side
Parameter
BPC-157
TB-500
Category
Tissue Repair
Tissue Repair
Evidence status
Preclinical
Clinical Trial
Sequence length
15
—
Molecular weight
1419.53 Da
4963.44 Da
Tissue Repair
BPC-157
Preclinical
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. First characterized in the 1990s, it is uniquely stable in stomach acid for over 24 hours — a property rare among peptides. Over three decades of preclinical research have demonstrated its healing and protective effects across multiple systems: accelerating tendon, ligament, and muscle repair, protecting the GI tract, promoting angiogenesis, and exerting neuroprotective activity through the VEGFR2-Akt-eNOS, FAK-paxillin, JAK-2/STAT, and ERK1/2 pathways. BPC-157 is not FDA-approved and remains an investigational research compound.
TB-500 is a synthetic version of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid peptide present in virtually all human and animal cells. Originally isolated from the thymus gland, Thymosin Beta-4 is the most abundant member of the beta-thymosin family and plays fundamental roles in cell migration, wound healing, and tissue repair through its primary function as a major actin-sequestering protein.
TB-500 contains the full Thymosin Beta-4 sequence with the critical active domain centered around the actin-binding motif LKKTETQ (amino acids 17-23), which is responsible for the peptide's ability to promote cell migration, angiogenesis, and tissue regeneration. Unlike many peptides, TB-500's mechanisms operate across virtually all tissue types — from cardiac and skeletal muscle to skin, cornea, and neural tissue.
The peptide has generated substantial research interest for its therapeutic potential in wound healing, cardiac repair following myocardial infarction, neurological recovery, and musculoskeletal injury. It is widely used in equine and veterinary medicine for tissue repair. TB-500 is not approved for human clinical use and is prohibited by WADA.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. First characterized in the 1990s, it is uniquely stable in stomach acid for over 24 hours — a property rare among peptides. Over three decades of preclinical research have demonstrated its healing and protective effects across multiple systems: accelerating tendon, ligament, and muscle repair, protecting the GI tract, promoting angiogenesis, and exerting neuroprotective activity through the VEGFR2-Akt-eNOS, FAK-paxillin, JAK-2/STAT, and ERK1/2 pathways. BPC-157 is not FDA-approved and remains an investigational research compound.
TB-500 is a synthetic version of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid peptide present in virtually all human and animal cells. Originally isolated from the thymus gland, Thymosin Beta-4 is the most abundant member of the beta-thymosin family and plays fundamental roles in cell migration, wound healing, and tissue repair through its primary function as a major actin-sequestering protein.
TB-500 contains the full Thymosin Beta-4 sequence with the critical active domain centered around the actin-binding motif LKKTETQ (amino acids 17-23), which is responsible for the peptide's ability to promote cell migration, angiogenesis, and tissue regeneration. Unlike many peptides, TB-500's mechanisms operate across virtually all tissue types — from cardiac and skeletal muscle to skin, cornea, and neural tissue.
The peptide has generated substantial research interest for its therapeutic potential in wound healing, cardiac repair following myocardial infarction, neurological recovery, and musculoskeletal injury. It is widely used in equine and veterinary medicine for tissue repair. TB-500 is not approved for human clinical use and is prohibited by WADA.